AA
ZYME icon

AlphaCentric Advisors’s Zymeworks ZYME Stock Holding History

AlphaCentric Advisors’s Portfolio ZYME Stock Details ZYME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-52,500
Closed -$413K – 220
2022
Q4 		$413K Buy
+52,500
New +$369K 0.41% 80
2021
Q2 		– Sell
-6,000
Closed -$189K – 244
2021
Q1 		$189K Buy
+6,000
New +$244K 0.06% 97

Other funds holding ZYME

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

AlphaCentric Advisors's ZYME Position: Q1 2023 in Review

AlphaCentric Advisors sold out of Zymeworks (ZYME) in Q1 2023, closing a stake of 52,500 shares — an estimated $413K sold.

AlphaCentric Advisors first reported a position in ZYME in Q1 2021 and held it in 2 quarters. The position peaked at $413K in Q4 2022. 115 funds tracked by Wall St. Rank hold ZYME as of Q1 2023.

  • AlphaCentric Advisors reported no remaining Zymeworks position as of Q1 2023 after selling out during the quarter.
  • AlphaCentric Advisors sold 52,500 Zymeworks shares in Q1 2023, an estimated $413K.
  • AlphaCentric Advisors first reported a position in Zymeworks in Q1 2021 and held it in 2 quarters.
  • AlphaCentric Advisors's Zymeworks position peaked at $413K in Q4 2022.
  • 115 funds tracked by Wall St. Rank held Zymeworks as of Q1 2023.

Based on AlphaCentric Advisors's 13F filing for Q1 2023, filed 12 May 2023.